GLP-1 News Today: What Has Changed (October 2026)

01 · The short version

GLP-1 news today: what actually matters

Three themes dominate current coverage: oral tablets, the next wave of drugs, and who can get treatment on the NHS. Each affects a different kind of reader, so it helps to decide which one applies to you.

02 · Your next step

Is this news relevant to you?

It is relevant if you are weighing up treatment and want to know which options are real today.

If you are already comparing options, our weight loss clinic explains how a consultation works. The Mounjaro pen starts at £169.99 per month at the 2.5mg dose, and new customers save £40 on their first order with code FIRST40. For a wider news view across brands, see our weight loss jabs news page.

03 · Oral tablets arrive

The new weight loss tablets

The new weight loss tablets are Wegovy tablets, which contain oral semaglutide, and Foundayo, which contains orforglipron. Both are oral GLP-1 medicines, and each has its own UK product information.²⁰²¹

Tablets appeal to people who dislike injections or find weekly pens inconvenient. They are different medicines from Mounjaro, with different dosing routines, so one trial result should never be lined up against another as if they were head to head.

If you prefer an injection, the Wegovy pen follows a stepped dose ladder of 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg, reaching the maintenance dose from week 17.

04 · The drug pipeline

Next-generation drugs: promising, not available

Next-generation GLP-1 drugs are in development, but none of them can be prescribed in the UK until it is licensed. Headlines describe candidates that act on several hormone receptors, and others designed to be injected less often than weekly.

These stories are worth following, yet early results do not tell you how a drug will perform in everyday use, how well it will be tolerated, or when it might be approved.

The practical advice is the same as ever. A licensed medicine you can start now, with proper monitoring, is more useful than a candidate that may or may not reach the UK. If you want the background on how this drug class works, our guides on the role of GLP-1 and what GLP-1 is are a good start.

05 · Mounjaro and the NHS

Mounjaro and the NHS: the current position

Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴⁶

Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting. If you are unsure where you fit, your GP is the right first conversation.

On the science, tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1.¹ In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² These are trial averages, and individual results vary. Treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.

06 · Supplements and hype

Natural GLP-1 boosters and the "poor man's Ozempic"

The phrase "poor man's Ozempic" is marketing for supplements such as berberine, which are not medicines. They are low-cost supplements with no clinical oversight, and their dosing is not standardised.

Foods rich in fibre and protein can help you feel full, and that is sensible dietary advice. But no food or supplement activates the receptors the way a licensed GLP-1 medicine does, and sellers who make dramatic weight-loss claims are not offering equivalent treatment. In the UK you can buy such supplements without any assessment, which is a reason for caution rather than reassurance.

Anyone offering to supply a prescription GLP-1 medicine without a consultation or prescription should be avoided. If you notice an unexpected symptom from any product, tell your prescriber and report it through the Yellow Card scheme.¹⁹

07 · Staying on treatment

How long can you stay on GLP-1 treatment?

How long you stay on treatment is a decision for you and your prescriber, based on your response, tolerance and goals. The SURMOUNT-1 trial ran for 72 weeks, but that is a trial length, not a limit on treatment.

Tirzepatide has a half-life of about five days, so after a final dose it takes roughly four to five weeks to clear the system. There is no way to speed this up, and nothing needs doing while it clears.¹ Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing.

Our ongoing monthly reviews let the prescribing team check dose, side effects and progress before each repeat order. If you have type 2 diabetes, tell your usual diabetes team as well so care stays joined up. For how the active ingredient behaves in the body, see our explainers on GLP-1 agonists and AMPK and GLP-1, or the more technical trapezoid GLP-1 overview.

08 · Reading headlines critically

How to read GLP-1 headlines critically

Start by asking whether a story is about a licensed UK medicine, an overseas product or a drug still in trials. These are very different things, and headlines often blur them.

Then check what was measured. Weight-loss averages describe groups, not individuals, and a result from one trial does not transfer to another medicine. Only a trial designed to compare two drugs directly supports a comparison between them.

Finally, look at who is speaking. Manufacturer announcements, regulator notices and peer-reviewed papers carry more weight than social posts or seller pages. When a claim promises specific results, treat it with suspicion.